



Revance Therapeutics  
Investor Relations Department  
7555 Gateway Boulevard  
Newark, CA 94560  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

#### NASDAQ: RVNC

Last Trade:	21.88
Trade Time:	2:55 PM ET May 26, 2017
Change:	0.63  (+2.941%)
Day Range	21.15 - 22.30
52-Week Range	12.35 - 24.30
Volume	269,388

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Revance, a Silicon Valley-based biotechnology company, is committed to the advancement of remarkable science. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance's science is based upon a proprietary TransMTS® peptide technology, which, when combined with active drug molecules, may help address current unmet needs.

Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthe... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

May 18, 2017

[Revance Announces Positive Top-Line 24-Week Duration of Effect Results in All Three Cohorts in RT002 Injectable Phase 2 Cervical Dystonia Trial](#)

May 9, 2017

[Revance Releases First Quarter 2017 Results](#)

May 1, 2017

[Revance Provides Update on Phase 2 Program for RT002 Injectable in the Management of Plantar Fasciitis](#)

Apr 25, 2017

[Revance Therapeutics to Release First Quarter 2017 Financial Results Tuesday, May 9, 2017](#)

Mar 7, 2017

[Revance Completes Enrollment in Phase 3 Pivotal Trials of RT002 Injectable for the Treatment of Glabellar \(Frown\) Lines](#)

## Financials [\[ View all \]](#)

[First Quarter Financial Results](#)

Feb 28, 2017

[Annual Report \(10-K\)](#)

Mar 24, 2017

[Proxy Statement \(DEF 14A\)](#)

May 9, 2017

[Quarterly Report \(10-Q\)](#)

Nov 4, 2016

[Quarterly Report \(10-Q\)](#)

Aug 5, 2016

[Quarterly Report \(10-Q\)](#)